Does more intensive therapy have effects on mantle cell lymphoma? A clinical experience from the Lymphoma Treatment Study Group in Japan

Int J Hematol. 2011 May;93(5):684-686. doi: 10.1007/s12185-011-0845-4. Epub 2011 Apr 12.

Authors

Affiliations

¹ Department of Hematology and Rheumatology, Division of Medicine, Nihon University School of Medicine, 30-1 Oyaguchikamicho, Itabashi-ku, Tokyo, Japan. [email protected].
² Lymphoma Treatment Study Group, Nara, Japan. [email protected].
³ Lymphoma Treatment Study Group, Nara, Japan.
⁴ Department of Hematology and Rheumatology, Division of Medicine, Nihon University School of Medicine, 30-1 Oyaguchikamicho, Itabashi-ku, Tokyo, Japan.

PMID: 21479980
DOI: 10.1007/s12185-011-0845-4

No abstract available

Publication types

Letter
Multicenter Study

MeSH terms

Aged
Aged, 80 and over
Antibodies, Monoclonal, Murine-Derived / administration & dosage*
Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
Chromosome Aberrations
Clinical Trials as Topic
Combined Modality Therapy / methods*
Cyclin D1 / biosynthesis*
Cyclophosphamide / administration & dosage
Doxorubicin / administration & dosage
Drug Administration Schedule
Female
Humans
Japan
Karyotyping
Lymphoma, Mantle-Cell / diagnosis
Lymphoma, Mantle-Cell / mortality
Lymphoma, Mantle-Cell / pathology
Lymphoma, Mantle-Cell / therapy*
Male
Middle Aged
Prednisone / administration & dosage
Retrospective Studies
Risk Factors
Rituximab
Stem Cell Transplantation*
Survival Analysis
Transplantation, Autologous
Vincristine / administration & dosage

Substances

Antibodies, Monoclonal, Murine-Derived
Cyclin D1
Rituximab
Vincristine
Doxorubicin
Cyclophosphamide
Prednisone

Supplementary concepts

CHOP protocol